Epigenetic Biomarkers in Colorectal Cancer Patients Receiving Adjuvant or Neoadjuvant Therapy: A Systematic Review of Epidemiological Studies
Colorectal cancer (CRC) represents the third-most common cancer worldwide and one of the main challenges for public health. Despite great strides in the application of neoadjuvant and adjuvant therapies for rectal and colon cancer patients, each of these treatments is still associated with certain a...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-08-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/20/15/3842 |
id |
doaj-f97d6c6cfedd4675a1e855bd6deeef63 |
---|---|
record_format |
Article |
spelling |
doaj-f97d6c6cfedd4675a1e855bd6deeef632020-11-25T02:20:27ZengMDPI AGInternational Journal of Molecular Sciences1422-00672019-08-012015384210.3390/ijms20153842ijms20153842Epigenetic Biomarkers in Colorectal Cancer Patients Receiving Adjuvant or Neoadjuvant Therapy: A Systematic Review of Epidemiological StudiesMartina Barchitta0Andrea Maugeri1Giovanni Li Destri2Guido Basile3Antonella Agodi4Department of Medical and Surgical Sciences and Advanced Technologies “GF Ingrassia”, University of Catania, via S. Sofia, 87, 95123 Catania, ItalyDepartment of Medical and Surgical Sciences and Advanced Technologies “GF Ingrassia”, University of Catania, via S. Sofia, 87, 95123 Catania, ItalyDepartment of Medical and Surgical Sciences and Advanced Technologies “GF Ingrassia”, University of Catania, via S. Sofia, 87, 95123 Catania, ItalyDepartment of General Surgery and Medical-Surgical Specialties, University of Catania, via S. Sofia, 78, 95123 Catania, ItalyDepartment of Medical and Surgical Sciences and Advanced Technologies “GF Ingrassia”, University of Catania, via S. Sofia, 87, 95123 Catania, ItalyColorectal cancer (CRC) represents the third-most common cancer worldwide and one of the main challenges for public health. Despite great strides in the application of neoadjuvant and adjuvant therapies for rectal and colon cancer patients, each of these treatments is still associated with certain adverse effects and different response rates. Thus, there is an urgent need for identifying novel potential biomarkers that might guide personalized treatments for specific subgroups of patients. However, until now, there are no biomarkers to predict the manifestation of adverse effects and the response to treatment in CRC patients. Herein, we provide a systematic review of epidemiological studies investigating epigenetic biomarkers in CRC patients receiving neoadjuvant or adjuvant therapy, and their potential role for the prediction of outcomes and response to treatment. With this aim in mind, we identified several epigenetic markers in CRC patients who received surgery with adjuvant or neoadjuvant therapy. However, none of them currently has the robustness to be translated into the clinical setting. Thus, more efforts and further large-size prospective studies and/or trials should be encouraged to develop epigenetic biomarker panels for personalized prevention and medicine in CRC cancer.https://www.mdpi.com/1422-0067/20/15/3842DNA methylationmiRNApreventionPublic HealthEpidemiologycolon cancerrectal cancerCIMP |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Martina Barchitta Andrea Maugeri Giovanni Li Destri Guido Basile Antonella Agodi |
spellingShingle |
Martina Barchitta Andrea Maugeri Giovanni Li Destri Guido Basile Antonella Agodi Epigenetic Biomarkers in Colorectal Cancer Patients Receiving Adjuvant or Neoadjuvant Therapy: A Systematic Review of Epidemiological Studies International Journal of Molecular Sciences DNA methylation miRNA prevention Public Health Epidemiology colon cancer rectal cancer CIMP |
author_facet |
Martina Barchitta Andrea Maugeri Giovanni Li Destri Guido Basile Antonella Agodi |
author_sort |
Martina Barchitta |
title |
Epigenetic Biomarkers in Colorectal Cancer Patients Receiving Adjuvant or Neoadjuvant Therapy: A Systematic Review of Epidemiological Studies |
title_short |
Epigenetic Biomarkers in Colorectal Cancer Patients Receiving Adjuvant or Neoadjuvant Therapy: A Systematic Review of Epidemiological Studies |
title_full |
Epigenetic Biomarkers in Colorectal Cancer Patients Receiving Adjuvant or Neoadjuvant Therapy: A Systematic Review of Epidemiological Studies |
title_fullStr |
Epigenetic Biomarkers in Colorectal Cancer Patients Receiving Adjuvant or Neoadjuvant Therapy: A Systematic Review of Epidemiological Studies |
title_full_unstemmed |
Epigenetic Biomarkers in Colorectal Cancer Patients Receiving Adjuvant or Neoadjuvant Therapy: A Systematic Review of Epidemiological Studies |
title_sort |
epigenetic biomarkers in colorectal cancer patients receiving adjuvant or neoadjuvant therapy: a systematic review of epidemiological studies |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1422-0067 |
publishDate |
2019-08-01 |
description |
Colorectal cancer (CRC) represents the third-most common cancer worldwide and one of the main challenges for public health. Despite great strides in the application of neoadjuvant and adjuvant therapies for rectal and colon cancer patients, each of these treatments is still associated with certain adverse effects and different response rates. Thus, there is an urgent need for identifying novel potential biomarkers that might guide personalized treatments for specific subgroups of patients. However, until now, there are no biomarkers to predict the manifestation of adverse effects and the response to treatment in CRC patients. Herein, we provide a systematic review of epidemiological studies investigating epigenetic biomarkers in CRC patients receiving neoadjuvant or adjuvant therapy, and their potential role for the prediction of outcomes and response to treatment. With this aim in mind, we identified several epigenetic markers in CRC patients who received surgery with adjuvant or neoadjuvant therapy. However, none of them currently has the robustness to be translated into the clinical setting. Thus, more efforts and further large-size prospective studies and/or trials should be encouraged to develop epigenetic biomarker panels for personalized prevention and medicine in CRC cancer. |
topic |
DNA methylation miRNA prevention Public Health Epidemiology colon cancer rectal cancer CIMP |
url |
https://www.mdpi.com/1422-0067/20/15/3842 |
work_keys_str_mv |
AT martinabarchitta epigeneticbiomarkersincolorectalcancerpatientsreceivingadjuvantorneoadjuvanttherapyasystematicreviewofepidemiologicalstudies AT andreamaugeri epigeneticbiomarkersincolorectalcancerpatientsreceivingadjuvantorneoadjuvanttherapyasystematicreviewofepidemiologicalstudies AT giovannilidestri epigeneticbiomarkersincolorectalcancerpatientsreceivingadjuvantorneoadjuvanttherapyasystematicreviewofepidemiologicalstudies AT guidobasile epigeneticbiomarkersincolorectalcancerpatientsreceivingadjuvantorneoadjuvanttherapyasystematicreviewofepidemiologicalstudies AT antonellaagodi epigeneticbiomarkersincolorectalcancerpatientsreceivingadjuvantorneoadjuvanttherapyasystematicreviewofepidemiologicalstudies |
_version_ |
1724871196232646656 |